🔗 Share this article

A shadow economy for unapproved slimming medications is propelled by social media fitness personalities and sellers on communication apps, according to recent findings.

Experimental Drug Gaining Popularity Via Social Media

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its alleged fat-burning properties. Viewers are encouraged to message these accounts privately for supplier links, while also obtaining discount codes.

Thriving Trade on Messaging Platforms

Additionally, a robust trade exists on Telegram, where groups with numerous of participants share comparison photos, administration instructions and claims of rapid UK delivery. Sellers market the substance there before directing buyers to WhatsApp for transactions.

Understanding The Experimental Drug

This medication is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist patients reduce up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the next Ozempic.

Healthcare Professionals Voice Worries

However, physicians and chemists have cautions that the distribution of what remains an unapproved medication in the UK is a cause for concern and could result in individuals administering products of unknown origin.

Some professionals stated the popularity for retatrutide could be linked to the increasing cost of approved weight loss treatments such as Mounjaro.

Regulatory Position and Implementation

Selling retatrutide on social media or Telegram is illegal in the United Kingdom, as it is an unapproved medication that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Several influencers try to circumvent the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still violate medicines, marketing, and consumer laws, risking fines, prosecution or imprisonment.

Platform Reaction and Material Elimination

According to TikTok, the platform has removed problematic content and prohibited related keywords and search suggestions. The company stated it was committed to keeping the platform safe and investing in strengthening compliance measures.

Digital Marketplace Activities

Research also found groups with up to nine thousand participants selling retatrutide using Telegram's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” instantly brings up groups with thousands of members, filled with photos of slimming results, glowing testimonials and detailed guides for mixing or injecting at home.

After moments of entering one group, a vendor posted contact information, where the majority of purchases take place. The seller provided an guidebook and promised delivery within two days. When asked whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a supposed testing documentation. Not one asked about weight, medical conditions or past usage.

Item Information and Costs

Inside these groups, messages show dark colored parcels with Royal Mail labels, claiming to contain new batches. One message read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, prepared at home with purified liquid, or pre-filled pens usually sold at £160 for 20mg. When asked how much time a injector should last, sellers give contradictory answers ranging from a several days to “depends on your body”.

Platform Moderation and Security Actions

A spokesperson for the messaging service stated it regularly moderated dangerous content on its service including material that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are administering substances they cannot confirm. Even if the research behind this drug is sound, these online products may not contain what they advertise,” stated Jason Murphy, the head of pharmaceutical services at a pharmacy service.

A medical professional of Asda Online Doctor linked the increase in interest to recent cost increases for approved slimming medications such as Mounjaro. “With prices rising, patients are turning to online platforms. But counterfeit treatments are highly risky. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she explained.

Her team has already seen patients harmed by self-injection from unconfirmed suppliers. “We understand the disappointment, but buying from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These materials could be contaminated or incorrectly dosed.”

Producer Statement

A representative from Eli Lilly stated the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Consequently at this point no one can sell [it] for personal consumption,” they explained, adding that any product “falsely representing itself as a company experimental product not yet authorized … may expose patients to potentially serious medical dangers”.